Q: Is Microsoft the new hot tech stock?
A: Tech bloggers have proudly boasted for years they knew nothing about Microsoft's products. But now, these same people are scrambling to see what they've been missing.
With a hip and young CEO with cloud and programming chops, Satya Nadella, Microsoft is now showing the world it has reinvented itself. Consumers are just now realizing it, but Wall Street has known for more than a year Microsoft is an undiscovered growth story in technology.
Shares of Microsoft have soared 43% over the past year, blowing away the 20% gain of the Standard & Poor's 500 and the 25% gain by Apple.
Top 10 Defensive Stocks To Buy Right Now: Bio-Path Holdings Inc (BPTH)
Bio-Path Holdings Inc is a development stage company. The Company, through its wholly owned subsidiary, Bio-Path, Inc. is engaged in the business of developing cancer therapeutics. As of December 31, 2011, the Company had licenses from The University of Texas M. D. Anderson Cancer Center (MD Anderson) for three lead products and nucleic acid delivery technology, including tumor targeting technology. The licenses provide drug delivery platform technology with composition of matter intellectual property for antisense that enables systemic delivery of antisense, formulation intellectual property for systemic delivery of small interfering Ribonucleic acid (RNA) (siRNA) and small molecules for treatment of cancer. The Company issued a press release announcing that the United States Food and Drug Administration (FDA) had allowed an IND (investigational new drug) for its lead cancer drug candidate liposomal BP-100-1.01 (or Liposomal Grb-2 or L-Grb-2) to proceed into clinical trials.
In February, 2012, the Company completed requirements for treating patients in the second cohort. The dose being used for treatment in the third cohort is double the dose that was used to treat patients in the second cohort. At the end of February, 2012, enrollment continued in the third cohort of the clinical trial and patients are being treated.
BP-100-1.01
BP-100-1.01 is the Company's lead lipid delivery antisense drug candidate, which is being clinically tested in patients having acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL). Receipt of an IND allowed the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients. Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center. As of December 31, 2011, the trial is in the middle of ! testing the third dose in patients.
BP-100-2.01
BP-100-1.02 is Liposomal Bcl-2 (also L-Bcl-2), another liposomal antisense drug candidate that was licensed from MD Anderson. This drug has pre-clinical testing data package. The target protein for this drug candidate, Bcl-2, is involved in regulating programmed cell death. In cancer, the Bcl-2 protein can over-express, which can lead to a situation, in which the Bcl-2 protein blocks the cell�� normal death signals, making the cancer cell resistant to chemotherapy. Types of cancer potentially treatable with L-Bcl-2 include lymphoma, prostate cancer, small cell lung cancer, breast cancer, melanoma, chronic lymphoid leukemia (CLL) and several others.
Advisors' Opinion:- [By Lisa Levin]
Bio-Path Holdings (NASDAQ: BPTH) shares declined 5.66% to touch a new 52-week low of $2.50. Bio-Path shares have jumped 349.15% over the past 52 weeks, while the S&P 500 index has gained 19.24% in the same period.
Best Tech Stocks To Watch Right Now: Inphi Corporation (IPHI)
Inphi Corporation provides high-speed analog and mixed signal semiconductor solutions for the communications, datacenter, and computing markets worldwide. Its analog and mixed signal semiconductor solutions offer high signal integrity at data speeds while reducing system power consumption. The company�s semiconductor solutions are designed to address bandwidth bottlenecks in networks, maximize throughput and minimize latency in computing environments, and enable the rollout of next generation communications, datacenter, and computing infrastructures. Its solutions provide a high-speed interface between analog signals and digital information in high-performance systems, such as telecommunications transport systems, enterprise networking equipment, datacenters and enterprise servers, storage platforms, test and measurement equipment, and military systems. The company also provides 40G and 100G high-speed analog semiconductor solutions for the communications market and high- speed memory interface solutions for the computing market. Its products include amplifiers and modulator drivers, clock and data recovery, isolation memory buffer, register, and SerDes products that perform a range of functions, such as amplifying, encoding, multiplexing, demultiplexing, retiming, and buffering data and clock signals at speeds up to 100 Gbps. Inphi Corporation sells its products directly through its sales force, as well as through a network of sales representatives and distributors to original equipment manufacturers. The company was formerly known as TCom Communications, Inc. and changed its name to Inphi Corporation in February 2001. Inphi Corporation was founded in 2000 and is headquartered in Santa Clara, California.
Advisors' Opinion:- [By Garrett Cook]
Inphi (NASDAQ: IPHI) shares were also up, gaining 33.19 percent to $17.04 after the company announced its plans to acquire Cortina Systems.
Equities Trading DOWN
Best Tech Stocks To Watch Right Now: ImmunoCellular Therapeutics Ltd (IMUC)
ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�� own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�� products include ICT-107, ICT-140, ICT-120, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�� immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).
The Company in addition to ICT-107, is also developing other therapeutic DC vaccines: ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-107 is a DC vaccine that targets six different tumor-associated antigens that are found on patients��tumor cells; four of the six antigens are expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. ICT-140 is a DC vaccine that targets seven different ovarian cancer antigens. ICT-121 is a DC vaccine that targets CD133 antigens; it has the potential to be a universal cancer vaccine because CD133 is widely expressed on CSCs from a majority of cancers. Data from this small study demonstrated that ICT-109 had a statistically ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets. The DIAAD (differential immunization for an! tigen and antibody discovery) platform it acquired from Molecular Discoveries utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The monoclonal antibodies produced by DIAAD provide the basis for the discovery and development of its potential diagnostic and therapeutic products.
The Company competes with Dendreon, Oncothyreon, Galena, Bavarian Nordic and Immunovaccine, Northwest Biotherapeutics, Prima Biomed, DCPrime, Roche/Genentech, Seattle Genetics, Bristol-Myers Squibb and Immunogen.
Advisors' Opinion:- [By Smith On Stocks]
Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.
- [By Monica Gerson]
ImmunoCellular Therapeutics (NYSE: IMUC) dropped 11.05% to $1.3699. ImmunoCellular's trailing-twelve-month ROE is -59.80%.
Posted-In: market losersNews Movers & Shakers Intraday Update Markets
- [By Wallace Witkowski]
Shares of ImmunoCellular (IMUC) �jumped after the drug developer said data on a mid-stage brain cancer drug study were looking encouraging.
- [By Lauren Pollock]
ImmunoCellular Therapeutics Ltd.(IMUC) said its leading product candidate, a dendritic cell-based vaccine for brain cancer, didn’t show a statistically significant advantage in overall survival in a Phase II study. In a research note, Maxim Group said it is pushing its EU approval date target to 2019 and lowered its estimate on the stock to $12 a share from $18 a share. The stock plunged 62% to $1.04 premarket.
Best Tech Stocks To Watch Right Now: Western Digital Corp (WDC)
Western Digital Corporation (WD) is a provider of solutions for the collection, storage, management, protection and use of digital content, including audio and video. Its principal products are hard drives, which are devices that use one or more rotating magnetic disks (magnetic media) to store and allow access to data. Its hard drives are used in desktop and notebook computers, corporate and cloud computing data centers, home entertainment equipment and stand-alone consumer storage devices. In addition to hard drives, its other products include solid-state drives and home entertainment and networking products. The Company operates as the parent company of its hard drive business, Western Digital Technologies, Inc. Effective March 8, 2012, the Company acquired Viviti Technologies Ltd. In May 2012, the Company completed the divestiture of certain 3.5-inch hard drive assets to Toshiba Corporation. As part of its deal with Toshiba, WD also completed its purchase of Toshiba Storage Device (Thailand) Company Limited (TSDT), which manufactured hard drives.
The Company offers a line of storage devices. Its hard drives include 3.5-inch and 2.5-inch form factors, capacities ranging from 80 gigabytes to three terabytes, nominal rotation speeds up to 10,000 revolutions per minute, and interfaces, such as Serial Advanced Technology Attachment (SATA) and Serial Attached SCSI (Small Computer System Interface) (SAS). In addition, the Company offers a family of hard drives specifically designed to consume less power than standard drives, utilizing its WD GreenPower Technology. Its solid-state drives include 2.5-inch and Compact Flash form factors, capacities ranging from 1 gigabyte to 256 gigabytes, and interfaces, such as SATA and PATA.
Client Compute Storage Products
Client compute consists of hard drives and solid-state drives for desktop and mobile personal computers (PC��). During the fiscal year ended July 1, 2011 (fiscal 2011), it shipped 151 million hard drive clie! nt compute unit. Its client compute storage products include WD Caviar, WD Scorpio and WD Silicon Edge. WD Caviar family of hard drives is designed for use in desktop PCs. WD Scorpio family of hard drives is designed for use in mobile PCs. WD Silicon Edge family of solid-state drives is designed for both read-intensive client/consumer applications and write-intensive original equipment manufacturer (OEM) applications.
Client Non-Compute Storage Products
Client non-compute consists of branded products and consumer electronics products. Its hard drive client non-compute unit shipments were 46 million, during fiscal 2011.
Branded Products
Branded products consists of hard drives embedded into WD-branded external storage appliances with capacities ranging from 250 gigabytes to 8 terabytes and using interfaces, such as Universal Serial Bus (USB) 2.0, USB 3.0, external SATA, FireWire and Ethernet network connections. Certain branded products models include software that assists customers with back up, remote access and management of digital content. Branded products also include its home entertainment and networking products. Its branded products include My Book and WD Elements Desktop family of storage appliances. My Passport and WD Elements Portable family of storage appliances include WD ShareSpace, WD TV and WD Livewire.
My Book and WD Elements Desktop family of storage appliances are designed to add external capacity to desktops and digital video recorders (DVRs), allow for the transfer and storage of videos directly from certain camcorders, and connect to networks to simplify storage for consumers. My Passport and WD Elements Portable family of storage appliances are designed for external portability weighing less than one-half of a pound and allow for the transfer and storage of videos directly from certain camcorders. WD ShareSpace is a network-attached storage system designed for home office or small office applications. WD TV m! edia play! ers connect to a user�� television or home theater system and play digital movies, music and photos from an integrated hard drive, network hard drives, any of its WD-branded external hard drives, other USB mass storage devices or content services accessed over the Internet. WD Livewire, which enables consumers to use their existing electrical outlets to extend Internet connections throughout the home.
Consumer Electronics Products
WD AV family of hard drives is designed for use in products, such as DVRs and audio and video applications. WD AV drives deliver the characteristics CE manufacturers.
Enterprise Storage Products
Enterprise consists of hard drives for traditional enterprise and nearline storage applications, as well as solid-state drives for embedded applications. Its hard drive enterprise unit shipments were 10 million, for fiscal 2011. Its enterprise storage products include WD S25 hard drive, WD VelociRaptor, WD RE and WD SiliconDrive. WD S25 hard drive is designed for mission-critical enterprise server and storage applications, such as data centers and data arrays. WD VelociRaptor hard drive is designed for enterprise server and storage applications. This hard drive is also used in the high-end desktop PC market for applications including gaming, servers and advanced computer-aided design/computer-aided manufacturing (CAD/CAM) systems. WD RE family of hard drives is designed for nearline storage enterprise applications. WD SiliconDrive family of solid-state drives features fast read/write speeds in high capacities and is designed for embedded system OEM applications.
The Company competes with Hitachi Global Storage Technologies, Intel Corporation, Micron Technology, Inc., Samsung Electronics Co. Ltd., Seagate Technology, STEC, Inc. and Toshiba Corporation.
Advisors' Opinion:- [By rusticnomad]
It would appear that Western Digital (WDC) is taking a walk on its arch-rival Seagate Technology (STX), as evident from the performance of their shares on the Street. While Seagate is up just 3% year-to-date, Western Digital is a clear leader with gains close to 18%. Moreover, relatively robust performance of Western Digital in the last reported quarter makes it a favorite of investors in digital-storage market segment.
- [By Piyush Arora]
An indifferent peer
Western Digital (NASDAQ: WDC ) , however, seems to be unaffected by this 3D NAND mania. Though the memory giant manufactures planar NAND drives, it has no intention of venturing into the 3D NAND space -- at least not yet. The company is betting on helium-filled hard drives to capture the enterprise-scale storage industry.� - [By Tim Brugger]
HGST, a wholly owned subsidiary of Western Digital (NASDAQ: WDC ) , has entered into an agreement whereby HGST will acquire a 100% ownership stake in sTec (NASDAQ: STEC ) in an all-cash transaction valued at $340 million, equal to $6.85 a share, the companies announced today.
Best Tech Stocks To Watch Right Now: Five Prime Therapeutics Inc (FPRX)
Five Prime Therapeutics, Inc., incorporated on December 20, 2001, is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company�� advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.
FP-1039
FP-1039 is a protein therapeutic, which includes the extracellular part of FGFR1. FP-1039 acts as an inhibitor of FGFs, because the FGFR1 portion of the molecule binds to FGFs and prevents them from binding to FGFR1 on tumor and blood vessel cells. Because FGF proteins circulating in the blood are called ligands, FP-1039 is called a ligand trap. FP-1039 also includes a portion of an antibody called the Fc region. In preclinical testing, it observed inhibition of tumor growth with single-agent FP-1039, particularly in tumors withFGFR1 gene amplification, including squamous NSCLC and SCLC.
FPA008
FPA008 is an antibody that inhibits CSF1R and is being developed to treat patients with RA. FPA008 also has the potential to treat patients with other inflammatory diseases, including lupus nephritis, psoriatic arthritis, ankylosing spondylitis, fibrosis, inflammatory bowel disease and multiple sclerosis. These are chronic, incurable disorders with serious medical complications and disability for ! which better therapies with novel mechanisms of action are needed. FPA008 is an anti-CSF1R antibody, which it designed to block the ability of IL-34 and CSF1 to bind to and activate CSF1R. FPA008 reduces the numbers and activity of monocytes and macrophages that cause disease, and prevents the production and release of inflammatory factors. The Company and others has demonstrated that both IL-34 and CSF1 are present at increased levels in the inflamed joints of patients with RA.
FPA144
FPA144 is a monoclonal antibody directed against a form of FGFR2, or FGFR2b. When the FGFR2 gene is amplified by cancer cells, the FGFR2b protein is expressed at abnormally high levels on the tumor�� surface. This occurs in some patients with gastric and lower esophageal cancers. The tumor cells that have too much FGFR2b protein on their surface can be identified by special staining tests performed on the tumor. Because FGFR2b is the target for FPA144, patients��tumors can be screened for this protein, helping to identify the patients most likely to respond to FPA144 treatment.
Advisors' Opinion:- [By Monica Gerson]
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) shares dropped 1.13% to $22.68 in pre-market trading after the company priced 3.41 million share offering at $22.00 per share.
Best Tech Stocks To Watch Right Now: Active Control Techn (ACTV)
The Active Network, Inc. provides organization-based cloud computing applications services to business customers in North America, Europe, and internationally. The company offers ActiveWorks, an organization-based cloud computing platform, which transforms the way organizers record, track, manage, and share information regarding activities and events. Its ActiveWorks back-office system pulls customers� participant management, operational reporting, volunteer management, and service and payment processing functions into one hosted system. The company also provides consulting services, which consist primarily of business mapping, project management services, and guidance on best practices in using its services; and implementation services, including system set-up and configuration, and data conversion, as well as develops customized training and education programs relating to both the use and administration of its services. It serves a range of customers, including communit y and sports organizations, large corporations, small and medium-sized businesses, educational institutions, federal and state government agencies, non-profit organizations, and other related entities. The company was formerly known as Racegate.com, Inc. and changed its name to The Active Network, Inc. in May 2001. The Active Network, Inc. was founded in 1998 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Lauren Pollock]
Among the companies with shares expected to actively trade in Monday’s session are Achillion Pharmaceuticals Inc.(ACHN), Active Network Inc.(ACTV) and Harvest Natural Resources Inc.(HNR)
- [By Luke Jacobi]
The Active Network (NYSE: ACTV) closed up 25.53 percent to $14.31 after the company agreed to be taken private by Vista Equity Partners for $1.05 billion.
- [By Selena Maranjian]
The biggest new holdings are Liberty Media�and AbbVie. Other new holdings of interest include The Active Network (NYSE: ACTV ) , which specializes in online registrations for endurance events such as marathons and triathlons. The company recently signed a three-year deal with Ironman, and its most recent quarterly earnings report featured revenue up 12% and shrinking losses. Some have questioned the company's solvency, while others like its valuation.
No comments:
Post a Comment